JP2012524770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524770A5 JP2012524770A5 JP2012506581A JP2012506581A JP2012524770A5 JP 2012524770 A5 JP2012524770 A5 JP 2012524770A5 JP 2012506581 A JP2012506581 A JP 2012506581A JP 2012506581 A JP2012506581 A JP 2012506581A JP 2012524770 A5 JP2012524770 A5 JP 2012524770A5
- Authority
- JP
- Japan
- Prior art keywords
- gal
- galactooligosaccharide
- glc
- inflammatory disease
- preventive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 25
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 25
- 208000027866 inflammatory disease Diseases 0.000 claims description 18
- DLRVVLDZNNYCBX-JZSVMVJISA-N beta-D-Galp-(1->6)-D-Galp Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-JZSVMVJISA-N 0.000 claims description 12
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 4
- 150000004043 trisaccharides Chemical class 0.000 claims description 4
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010051606 Necrotising colitis Diseases 0.000 claims description 3
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims description 3
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 208000007784 diverticulitis Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000002554 disease preventive effect Effects 0.000 claims 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0906983.2 | 2009-04-23 | ||
| GBGB0906983.2A GB0906983D0 (en) | 2009-04-23 | 2009-04-23 | Novel use |
| GB0920784.6 | 2009-11-27 | ||
| GBGB0920784.6A GB0920784D0 (en) | 2009-04-23 | 2009-11-27 | Novel use |
| PCT/GB2010/050659 WO2010122344A1 (en) | 2009-04-23 | 2010-04-23 | Novel use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012524770A JP2012524770A (ja) | 2012-10-18 |
| JP2012524770A5 true JP2012524770A5 (enExample) | 2013-06-06 |
Family
ID=40774842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506581A Pending JP2012524770A (ja) | 2009-04-23 | 2010-04-23 | 新規な使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20120058972A1 (enExample) |
| EP (1) | EP2421541B1 (enExample) |
| JP (1) | JP2012524770A (enExample) |
| KR (1) | KR20110138416A (enExample) |
| CN (1) | CN102427818A (enExample) |
| AU (1) | AU2010240642B2 (enExample) |
| BR (1) | BRPI1015091A2 (enExample) |
| CA (1) | CA2759442C (enExample) |
| CY (1) | CY1120597T1 (enExample) |
| DK (1) | DK2421541T3 (enExample) |
| ES (1) | ES2688786T3 (enExample) |
| GB (3) | GB0906983D0 (enExample) |
| HU (1) | HUE040451T2 (enExample) |
| IL (1) | IL215855A0 (enExample) |
| MX (1) | MX341308B (enExample) |
| MY (1) | MY151104A (enExample) |
| NZ (1) | NZ595969A (enExample) |
| PL (1) | PL2421541T3 (enExample) |
| PT (1) | PT2421541T (enExample) |
| RU (1) | RU2530567C2 (enExample) |
| SG (1) | SG175313A1 (enExample) |
| TR (1) | TR201810868T4 (enExample) |
| UA (1) | UA106491C2 (enExample) |
| WO (1) | WO2010122344A1 (enExample) |
| ZA (1) | ZA201107821B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2492559B (en) * | 2011-07-05 | 2018-07-25 | Clasado Inc | Composition and method for preventing or reducing the risk of developing a syndrome |
| BR112014001472A2 (pt) | 2011-07-22 | 2017-02-21 | Abbott Lab | galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal |
| CN103716787B (zh) | 2012-09-29 | 2020-06-23 | 北京三星通信技术研究有限公司 | 一种支持对家用基站进行验证的方法 |
| CA2983236A1 (en) | 2015-04-23 | 2016-10-27 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
| CN107158011A (zh) * | 2017-05-25 | 2017-09-15 | 浙江大学 | 低聚半乳糖在制备治疗肠道疾病的药物中的用途 |
| BR112021022447A2 (pt) * | 2019-05-15 | 2021-12-28 | Nutricia Nv | Métodos para aumentar a função da barreira intestinal e/ou para a prevenção e/ou o tratamento de ruptura da barreira intestinal, método para o tratamento, a prevenção e/ou o alívio de uma condição associado à exposição a toxinas, fórmula infantil, fórmula de seguimento ou fórmula para criança de primeira infância, trissacarídeos, composições nutricionais, uso do trissacarídeo e usos de uma composição nutricional |
| US20240277739A1 (en) * | 2021-07-01 | 2024-08-22 | N.V. Nutricia | Nutritonal compositions for gut barrier function |
| KR102453998B1 (ko) * | 2022-01-07 | 2022-10-14 | (주)네오크레마 | 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물 |
| GB2619977A (en) * | 2022-06-24 | 2023-12-27 | Clasado Res Services Limited | Compositions and uses thereof |
| GB2623336A (en) * | 2022-10-12 | 2024-04-17 | Clasado Res Services Limited | Compositions and uses thereof |
| GB2623335A (en) * | 2022-10-12 | 2024-04-17 | Clasado Res Services Limited | Compositions and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| GB0315266D0 (en) * | 2003-06-30 | 2003-08-06 | Clasado Inc | Novel galactooligosaccharide composition and the preparation thereof |
| EP1644482B2 (en) * | 2003-06-30 | 2014-10-01 | Clasado Inc. | Novel galactooligosaccharide composition and the preparation thereof |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| EP1887017A1 (en) * | 2006-08-09 | 2008-02-13 | Friesland Brands B.V. | Prebiotic carbohydrate |
| GB0809921D0 (en) * | 2008-05-30 | 2008-07-09 | Clasado Inc | Product and process therefor |
-
2009
- 2009-04-23 GB GBGB0906983.2A patent/GB0906983D0/en not_active Ceased
- 2009-11-27 GB GBGB0920784.6A patent/GB0920784D0/en not_active Ceased
-
2010
- 2010-04-23 US US13/265,532 patent/US20120058972A1/en not_active Abandoned
- 2010-04-23 RU RU2011147390/15A patent/RU2530567C2/ru not_active IP Right Cessation
- 2010-04-23 BR BRPI1015091A patent/BRPI1015091A2/pt not_active Application Discontinuation
- 2010-04-23 GB GB1120030.0A patent/GB2482817B/en active Active
- 2010-04-23 PT PT10714956T patent/PT2421541T/pt unknown
- 2010-04-23 MY MYPI2011004912 patent/MY151104A/en unknown
- 2010-04-23 CA CA2759442A patent/CA2759442C/en active Active
- 2010-04-23 DK DK10714956.9T patent/DK2421541T3/en active
- 2010-04-23 UA UAA201113760A patent/UA106491C2/uk unknown
- 2010-04-23 JP JP2012506581A patent/JP2012524770A/ja active Pending
- 2010-04-23 TR TR2018/10868T patent/TR201810868T4/tr unknown
- 2010-04-23 CN CN2010800180409A patent/CN102427818A/zh active Pending
- 2010-04-23 EP EP10714956.9A patent/EP2421541B1/en not_active Revoked
- 2010-04-23 MX MX2011011159A patent/MX341308B/es active IP Right Grant
- 2010-04-23 NZ NZ595969A patent/NZ595969A/xx not_active IP Right Cessation
- 2010-04-23 PL PL10714956T patent/PL2421541T3/pl unknown
- 2010-04-23 AU AU2010240642A patent/AU2010240642B2/en active Active
- 2010-04-23 HU HUE10714956A patent/HUE040451T2/hu unknown
- 2010-04-23 WO PCT/GB2010/050659 patent/WO2010122344A1/en not_active Ceased
- 2010-04-23 KR KR1020117027762A patent/KR20110138416A/ko not_active Ceased
- 2010-04-23 ES ES10714956.9T patent/ES2688786T3/es active Active
- 2010-04-23 SG SG2011077443A patent/SG175313A1/en unknown
-
2011
- 2011-10-23 IL IL215855A patent/IL215855A0/en unknown
- 2011-10-25 ZA ZA2011/07821A patent/ZA201107821B/en unknown
-
2018
- 2018-08-13 CY CY181100857T patent/CY1120597T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524770A5 (enExample) | ||
| US10758561B2 (en) | Composition based on xyloglucan and proteins for the treatment of intestinal disorders | |
| JP2012518635A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| RU2011147390A (ru) | Новое применение | |
| RU2015103723A (ru) | Продукт применения в профилактическом или терапевтическом лечении отрицательных эмоций или интровертного поведения | |
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2012502047A5 (enExample) | ||
| Jamialahmadi et al. | Glucosamine alleviates scopolamine induced spatial learning and memory deficits in rats | |
| JP2020500864A5 (enExample) | ||
| KR20010020413A (ko) | 위궤양에 대한 아연 히알루로네이트의 사용 | |
| US11304918B2 (en) | Methods and compositions for the treatment of diverticulosis | |
| JP2016512247A5 (enExample) | ||
| RU2501549C1 (ru) | Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни | |
| US20150094266A1 (en) | Xyloglucan and protein compositions for the treatment of intestinal disorders | |
| Stepanović-Petrović et al. | Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model | |
| Adelinik et al. | The Role of Microbial Metabolites in Cancer and Inflammatory Diseases: Interaction with the Immune System | |
| WO2011100668A4 (en) | Methods and compositions of civamide to treat diseases of the intestines | |
| Hatakeyama et al. | Multiple mediators and mechanisms are involved in the adaptive cytoprotection provided by certain mild irritants | |
| Son et al. | A case of acute pancreatitis induced by multiple drugs in a patient with ulcerative colitis | |
| CA3229004A1 (en) | Compositions and methods for preventing or reducing the risk of metabolic syndrome | |
| El Azazy et al. | Modulation of neuroinflammation by inulin and magnesium in a rotenone-induced Parkinson’s disease model | |
| JP2017066142A (ja) | 止瀉剤組成物 | |
| Salam | Angiotensin receptor blockers in acute myocardial infarction | |
| PIÑA | Supra-additive interaction of docosahexaenoic acid and naproxen and gastric safety on the formalin test in rats |